Zenas BioPharma heads into its May 15 results with one of the most aggressive short-interest builds in recent memory — and a CEO who has been buying into the decline with his own cash.
Short sellers have dramatically increased pressure over the past month. At nearly 20% of the free float, short interest has climbed 17% in a single week and more than 20% over the past month. The ORTEX short score of 82.8 ranks in the second percentile of the broader universe — meaning almost every other stock carries less short-side conviction than ZBIO right now. Borrow availability has eased from the lows seen in April, when the lending pool was far tighter, and cost to borrow has pulled back to 0.81% — low in absolute terms — suggesting the supply of lendable shares is adequate even as new shorts pile in. Options positioning is mildly defensive, with the put/call ratio at 0.63, just above its 20-day average of 0.59, and well off the 52-week high of 2.03. The hedging signal is present but not alarming.
The bullish case for obexelimab is concrete. The lead drug candidate — targeting relapsing MS and IgG4-related disease — produced a 56% reduction in IgG4-RD flare risk and a 93% ongoing remission rate in Phase 2. Bulls assign rising probability of regulatory success and increasingly premium pricing assumptions. Morgan Stanley moved modestly higher yesterday, lifting its Equal-Weight target from $21 to $22, but the neutral stance frames the debate: even a sympathetic reading of the data leaves conviction split. Consensus mean target is $42.12, more than double the current $18.90 price — a gap large enough to reflect genuine fundamental disagreement rather than a simple valuation reset. Guggenheim holds a $55 target; Citigroup sits at $41 with a Buy. Bears point to execution risk, capital needs, and the competitive immunology landscape (citing Sanofi setbacks as a cautionary read-through).
The ownership picture sharpens the picture meaningfully. CEO Lonnie Moulder purchased 60,000 shares across two sessions in late April — spending roughly $1.07 million — at prices between $17.62 and $18.02. That followed a further $656,000 buy from Moulder on March 31, when he also bought 34,000 shares at $19.31. Combined with $1.5 million from a board-linked venture capital buyer on the same day, net insider buying over the past 90 days totals more than $8.7 million. That is a consequential signal for a pre-revenue biotech of this size. FMR (Fidelity) added nearly 2.9 million shares in its most recently reported period, making it the largest institutional holder at 12.9%.
The print is therefore a test of which side of that fundamental divide proves better-informed — whether the Phase 2 data translates into a credible path to commercialization, or whether capital runway and competitive pressure justify the heaviest short build the stock has seen in months.
See the live data behind this article on ORTEX.
Open ZBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
